Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. November 2012 16:00 ET | Quelle: Mateon Therapeutics

OXiGENE Announces Phase 2 Data on ZYBRESTAT to Treat the Eye Disease, Polypoidal Choroidal Vasculopathy (PCV), Presented at the American Academy of Ophthalmology 2012 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
08. November 2012 16:00 ET | Quelle: Mateon Therapeutics

OXiGENE Reports Third Quarter 2012 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 8, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial...
05. November 2012 16:05 ET | Quelle: Mateon Therapeutics

OXiGENE Announces Presentation at BIO-Europe Conference on November 14th

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
01. November 2012 09:30 ET | Quelle: Mateon Therapeutics

OXiGENE Announces Third Quarter 2012 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., Nov. 1, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report third...
17. September 2012 16:00 ET | Quelle: Mateon Therapeutics

OXiGENE Announces Agreement With FDA on Special Protocol Assessment for a Phase 3 Trial of ZYBRESTAT(R) in Anaplastic Thyroid Cancer

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that it...
07. September 2012 06:00 ET | Quelle: Mateon Therapeutics

OXiGENE to Present Data Showing Importance of Local Site Pathology Confirmation in Phase 2/3 Clinical Trial of Zybrestat(R) in Anaplastic Thyroid Cancer

SOUTH SAN FRANCISCO, Calif., Sept. 7, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
22. August 2012 16:00 ET | Quelle: Mateon Therapeutics

OXiGENE Expands ZYBRESTAT Named Patient Program With Azanta A/S

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that the...
08. August 2012 16:00 ET | Quelle: Mateon Therapeutics

OXiGENE Reports Second Quarter 2012 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 8, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial...
06. August 2012 06:00 ET | Quelle: Mateon Therapeutics

OXiGENE Announces Phase 2 Ovarian Cancer Trial of ZYBRESTAT(R) Plus Bevacizumab Achieves Important Interim Safety Objective

SOUTH SAN FRANCISCO, Calif., Aug. 6, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today...
27. Juni 2012 06:00 ET | Quelle: Mateon Therapeutics

OXiGENE Receives Notice Related to NASDAQ Minimum Closing Bid Price Rule

SOUTH SAN FRANCISCO, Calif., June 27, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced it has...

Vorherige Seite

Nächste Seite